FIDAS-5
Based on 9 publication(s) in Google Scholar
FIDAS-5 is a potent and orally active methionine S-adenosyltransferase 2A (MAT2A) inhibitor with an IC50 of 2.1 μM. FIDAS-5 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding. FIDAS-5 has anticancer activities.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 98.46%
- CAS 番号: 1391934-98-7
- 分子式: C15H13ClFN
- 分子量:261.72
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years
* The compound is unstable in solutions, freshly prepared is recommended.
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 FIDAS-5
More- Cell Metab. 2026 Feb 3;38(2):298-315.e6. [Abstract]
- Nat Metab. 2026 Jan;8(1):237-259. [Abstract]
- Nat Metab. 2023 Nov;5(11):1911-1930. [Abstract]
- Nat Neurosci. 2026 Jun 26. [Abstract]
- Sci China Life Sci. 2026 May;69(5):1604-1619. [Abstract]
- Food Funct. 2025 Oct 27. [Abstract]
- Development. 2023 Oct 15;150(20):dev201135. [Abstract]
- bioRxiv. 2026 Feb 18:2026.02.16.706212. [Abstract]
- bioRxiv. 2024 September 03.
Customer Validation & Images
-
In Vivo Efficacy Study
-
WB
-
WB
-
Histological Imaging/Staining
生物活性
IC50: 2.1 μM (Methionine S-adenosyltransferase 2A (MAT2A))[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | IC50 |
49.8 μM
Compound: 2b
|
Inhibition of human ERG over-expressed in HEK293 cell membrane by [3H]dofetilide binding assay
Inhibition of human ERG over-expressed in HEK293 cell membrane by [3H]dofetilide binding assay
|
[PMID: 24950374] |
| LS174T | IC50 |
7.6 nM
Compound: 2b
|
Antiproliferative activity against human LS 174T cells by cell viability analyzer
Antiproliferative activity against human LS 174T cells by cell viability analyzer
|
[PMID: 24950374] |
FIDAS-5 (3 μM; 7 days; LS174T cells) treatment significantly inhibits the proliferation of LS174T cells[1].
FIDAS-5 (3 μM) treatment inhibits the expression of c-Myc and cyclinD1 in LS174T CRC cells. And FIDAS-5 induces the expression of cell cycle inhibitor, p21WAF1/CIP1[1].
FIDAS-5 (3 μM; 36 h) treatment reduces the levels of both S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) in LS174T cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:LS174T colorectal cancer (CRC) cells
-
Concentration:3 μM
-
Incubation Time:7 days
-
Result:Significantly inhibited the proliferation of LS174T cells.
Mice are treated with FIDAS-5 (20 mg/kg) for 1 week. The liver SAM levels are significantly reduced[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:16 athymic nude mice injected with HT29 CRC cells[1]
-
Dosage:20 mg/kg
-
Administration:Oral gavage; daily; for two weeks
-
Result:Significantly inhibited the growth of xenograft tumors.
化学情報
-
CAS 番号 1391934-98-7
-
性状 Solid
-
分子量 261.72
-
分子式 C15H13ClFN
-
Color Light yellow to yellow
-
SMILES
CNC1=CC=C(/C=C/C2=C(F)C=CC=C2Cl)C=C1
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years * The compound is unstable in solutions, freshly prepared is recommended.
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Cell Metab
Dietary methionine mitigates immune-mediated damage by enhancing renal clearance of cytokines. [Abstract]2026 Feb 3;38(2):298-315.e6. PMID: 41576934
FIDAS-5 purchased from MedChemExpress. Usage Cited in: Cell Metab. 2026 Feb 3;38(2):298-315.e6. [Abstract]
Survival of infected mice treated with either vehicle or FIDAS-5 (40 mg/kg).
-
Nat Metab
Multi-omics profiling of cachexia-targeted tissues reveals a spatio-temporally coordinated response to cancer. [Abstract]2026 Jan;8(1):237-259. PMID: 41540255
FIDAS-5 purchased from MedChemExpress. Usage Cited in: Nat Metab. 2026 Jan;8(1):237-259. [Abstract]
C2C12 myotubes were treated with 100 ng/mL recombinant IL-6 and varying doses of FIDAS-5 for 48 hours. Activation of the rIL-6 signaling cascade was verified by assessing pY705-STAT3 protein levels.
-
Nat Metab
2023 Nov;5(11):1911-1930. PMID: 37973897
FIDAS-5 purchased from MedChemExpress. Usage Cited in: Nat Metab. 2023 Nov;5(11):1911-1930. [Abstract]
On day 14 after DSS treatment, the recovery of colonic homeostasis in the FIDAS-5 (MAT2Ai: 20 mg/kg) group was evaluated using H&E staining.
-
Nat Neurosci
The mitochondrial unfolded protein response in human microglia disrupts neuronal-glial communication and promotes senescence. [Abstract]2026 Jun 26. PMID: 42362883 -
Sci China Life Sci
2026 May;69(5):1604-1619. PMID: 41793590
FIDAS-5 purchased from MedChemExpress. Usage Cited in: Sci China Life Sci. 2026 May;69(5):1604-1619. [Abstract]
iBMDM cells were cultured as indicated for cell viability, LDH release, and Western blot analyses. iBMDM cells were pre-cultured with Z-VAD-FMK before exposure to FIDAS-5 or PF-9366. Actin was the loading control.
-
Food Funct
Methionine restriction attenuates renal injury by suppressing macrophage polarization via IRF1 downregulation. [Abstract]2025 Oct 27. PMID: 41140247 -
Development
S-adenosyl-L-methionine supplementation alleviates the destructed intestinal epithelium and inflammatory infiltration caused by Mat2a deficiency. [Abstract]2023 Oct 15;150(20):dev201135. PMID: 36975381 -
bioRxiv
Radiation synergizes with BET inhibition to stimulate durable, systemic anti-tumor immunity in murine cancer models. [Abstract]2026 Feb 18:2026.02.16.706212. PMID: 41757027 -
溶剤 & 溶解度
DMSO : 125 mg/mL (477.61 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (7.95 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (7.95 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * The compound is unstable in solutions, freshly prepared is recommended.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.8209 mL | 19.1044 mL | 38.2088 mL | 95.5219 mL |
| 5 mM | 0.7642 mL | 3.8209 mL | 7.6418 mL | 19.1044 mL | |
| 10 mM | 0.3821 mL | 1.9104 mL | 3.8209 mL | 9.5522 mL | |
| 15 mM | 0.2547 mL | 1.2736 mL | 2.5473 mL | 6.3681 mL | |
| 20 mM | 0.1910 mL | 0.9552 mL | 1.9104 mL | 4.7761 mL | |
| 25 mM | 0.1528 mL | 0.7642 mL | 1.5284 mL | 3.8209 mL | |
| 30 mM | 0.1274 mL | 0.6368 mL | 1.2736 mL | 3.1841 mL | |
| 40 mM | 0.0955 mL | 0.4776 mL | 0.9552 mL | 2.3880 mL | |
| 50 mM | 0.0764 mL | 0.3821 mL | 0.7642 mL | 1.9104 mL | |
| 60 mM | 0.0637 mL | 0.3184 mL | 0.6368 mL | 1.5920 mL | |
| 80 mM | 0.0478 mL | 0.2388 mL | 0.4776 mL | 1.1940 mL | |
| 100 mM | 0.0382 mL | 0.1910 mL | 0.3821 mL | 0.9552 mL |
Powered by Bioz